Aurinia Pharmaceuticals (AUPH) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed Aurinia Pharmaceuticals (AUPH) over the past year, gaining 495.3% versus a gain of 36.7%. Over five years, SLS leads with a +28.1% price change compared with -22.2% for AUPH. SELLAS Life Sciences Group is the larger company by market cap ($2.27 billion vs $2.16 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | SLS |
|---|---|---|
| Share price | $16.22 | $11.26 |
| Market cap | $2.16B | $2.27B |
| 1-day change | +1.31% | -0.44% |
| YTD return | +0.38% | +200.00% |
| 1-year return | +36.72% | +495.26% |
| 5-year return | -22.17% | +28.09% |
| P/E ratio (TTM) | 7.11 | — |
| Forward P/E | 15.21 | — |
| EPS (TTM) | $2.28 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.25 | $15.88 |
| 52-week low | $10.90 | $1.39 |
| Distance from 52-week high | -15.74% | -29.09% |
| Analyst consensus | none | none |
| Avg. price target upside | +10.11% | +188.63% |
| Average volume | 988.90K | 6.56M |
| Shares outstanding | 133.05M | 201.95M |
| Employees | 128 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed AUPH by 458.5 percentage points over the past year.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
AUPH vs SLS FAQ
Which is bigger, Aurinia Pharmaceuticals or SELLAS Life Sciences Group?
SELLAS Life Sciences Group (SLS) is larger, with a market capitalization of $2.27B compared with $2.16B for Aurinia Pharmaceuticals (AUPH).
Which stock has performed better over the past year, AUPH or SLS?
SLS returned +495.26% over the past 12 months, compared with +36.72% for AUPH (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and SELLAS Life Sciences Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.